Oryzon Proposes €125M Capital Increase; Shares Drop 7%

Oryzon, a Spanish biotech, has proposed another €125 million capital increase to its board, following prior dilutive raises. Shares fell over 7% on the announcement, reflecting investor concern over dilution and financing strategy. The move signals ongoing cash burn and potential equity overhang.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works